Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

October 2022; 8 (5) ReviewOpen Access

Overview of the Clinical Approach to Individuals With Cerebellar Ataxia and Neuropathy

Leslie J. Roberts, Michael McVeigh, Linda Seiderer, Ian H. Harding, View ORCID ProfileLouise A. Corben, Martin Delatycki, David J. Szmulewicz
First published September 28, 2022, DOI: https://doi.org/10.1212/NXG.0000000000200021
Leslie J. Roberts
From the Neurophysiology Department (L.J.R.,L.S.), Department of Neurology & Neurological Research, St Vincent's Hospital; Department of Medicine (L.J.R., L.S.), the University of Melbourne; Ballance Disorders and Ataxia Service (L.J.R., M.M., D.J.S.), Eye and Ear Hospital; Department of Neuroscience (I.H.H., L.A.C.), Central Clinical School, Monash University; Monash Biomedical Imaging (I.H.H., L.A.C.), Monash University; Bruce Lefroy Centre (L.A.C.), Murdoch Children's Research Institute; 7Department of Paediatrics, Melbourne University; Turner Institute for Brain and Mental Health, Monash University; Victorian Clinical Genetics Services (M.D.), Murdoch Children's Reseach Institute; and The Florey Institute of Neuroscience and Mental Health (D.J.S.), the University of Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lesroberts1@bigpond.com
Michael McVeigh
From the Neurophysiology Department (L.J.R.,L.S.), Department of Neurology & Neurological Research, St Vincent's Hospital; Department of Medicine (L.J.R., L.S.), the University of Melbourne; Ballance Disorders and Ataxia Service (L.J.R., M.M., D.J.S.), Eye and Ear Hospital; Department of Neuroscience (I.H.H., L.A.C.), Central Clinical School, Monash University; Monash Biomedical Imaging (I.H.H., L.A.C.), Monash University; Bruce Lefroy Centre (L.A.C.), Murdoch Children's Research Institute; 7Department of Paediatrics, Melbourne University; Turner Institute for Brain and Mental Health, Monash University; Victorian Clinical Genetics Services (M.D.), Murdoch Children's Reseach Institute; and The Florey Institute of Neuroscience and Mental Health (D.J.S.), the University of Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: 11mmcv@gmail.com
Linda Seiderer
From the Neurophysiology Department (L.J.R.,L.S.), Department of Neurology & Neurological Research, St Vincent's Hospital; Department of Medicine (L.J.R., L.S.), the University of Melbourne; Ballance Disorders and Ataxia Service (L.J.R., M.M., D.J.S.), Eye and Ear Hospital; Department of Neuroscience (I.H.H., L.A.C.), Central Clinical School, Monash University; Monash Biomedical Imaging (I.H.H., L.A.C.), Monash University; Bruce Lefroy Centre (L.A.C.), Murdoch Children's Research Institute; 7Department of Paediatrics, Melbourne University; Turner Institute for Brain and Mental Health, Monash University; Victorian Clinical Genetics Services (M.D.), Murdoch Children's Reseach Institute; and The Florey Institute of Neuroscience and Mental Health (D.J.S.), the University of Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: linda.seiderer@svha.org.au
Ian H. Harding
From the Neurophysiology Department (L.J.R.,L.S.), Department of Neurology & Neurological Research, St Vincent's Hospital; Department of Medicine (L.J.R., L.S.), the University of Melbourne; Ballance Disorders and Ataxia Service (L.J.R., M.M., D.J.S.), Eye and Ear Hospital; Department of Neuroscience (I.H.H., L.A.C.), Central Clinical School, Monash University; Monash Biomedical Imaging (I.H.H., L.A.C.), Monash University; Bruce Lefroy Centre (L.A.C.), Murdoch Children's Research Institute; 7Department of Paediatrics, Melbourne University; Turner Institute for Brain and Mental Health, Monash University; Victorian Clinical Genetics Services (M.D.), Murdoch Children's Reseach Institute; and The Florey Institute of Neuroscience and Mental Health (D.J.S.), the University of Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ian.harding@monash.edu
Louise A. Corben
From the Neurophysiology Department (L.J.R.,L.S.), Department of Neurology & Neurological Research, St Vincent's Hospital; Department of Medicine (L.J.R., L.S.), the University of Melbourne; Ballance Disorders and Ataxia Service (L.J.R., M.M., D.J.S.), Eye and Ear Hospital; Department of Neuroscience (I.H.H., L.A.C.), Central Clinical School, Monash University; Monash Biomedical Imaging (I.H.H., L.A.C.), Monash University; Bruce Lefroy Centre (L.A.C.), Murdoch Children's Research Institute; 7Department of Paediatrics, Melbourne University; Turner Institute for Brain and Mental Health, Monash University; Victorian Clinical Genetics Services (M.D.), Murdoch Children's Reseach Institute; and The Florey Institute of Neuroscience and Mental Health (D.J.S.), the University of Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Louise A. Corben
  • For correspondence: louise.corben@mcri.edu.au
Martin Delatycki
From the Neurophysiology Department (L.J.R.,L.S.), Department of Neurology & Neurological Research, St Vincent's Hospital; Department of Medicine (L.J.R., L.S.), the University of Melbourne; Ballance Disorders and Ataxia Service (L.J.R., M.M., D.J.S.), Eye and Ear Hospital; Department of Neuroscience (I.H.H., L.A.C.), Central Clinical School, Monash University; Monash Biomedical Imaging (I.H.H., L.A.C.), Monash University; Bruce Lefroy Centre (L.A.C.), Murdoch Children's Research Institute; 7Department of Paediatrics, Melbourne University; Turner Institute for Brain and Mental Health, Monash University; Victorian Clinical Genetics Services (M.D.), Murdoch Children's Reseach Institute; and The Florey Institute of Neuroscience and Mental Health (D.J.S.), the University of Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: martin.delatycki@vcgs.org.au
David J. Szmulewicz
From the Neurophysiology Department (L.J.R.,L.S.), Department of Neurology & Neurological Research, St Vincent's Hospital; Department of Medicine (L.J.R., L.S.), the University of Melbourne; Ballance Disorders and Ataxia Service (L.J.R., M.M., D.J.S.), Eye and Ear Hospital; Department of Neuroscience (I.H.H., L.A.C.), Central Clinical School, Monash University; Monash Biomedical Imaging (I.H.H., L.A.C.), Monash University; Bruce Lefroy Centre (L.A.C.), Murdoch Children's Research Institute; 7Department of Paediatrics, Melbourne University; Turner Institute for Brain and Mental Health, Monash University; Victorian Clinical Genetics Services (M.D.), Murdoch Children's Reseach Institute; and The Florey Institute of Neuroscience and Mental Health (D.J.S.), the University of Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Overview of the Clinical Approach to Individuals With Cerebellar Ataxia and Neuropathy
Leslie J. Roberts, Michael McVeigh, Linda Seiderer, Ian H. Harding, Louise A. Corben, Martin Delatycki, David J. Szmulewicz
Neurol Genet Oct 2022, 8 (5) e200021; DOI: 10.1212/NXG.0000000000200021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
939

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Increasingly, cerebellar syndromes are recognized as affecting multiple systems. Extracerebellar features include peripheral neuropathies affecting proprioception; cranial neuropathies such as auditory and vestibular; and neuronopathies, for example, dorsal root and vestibular. The presence of such features, which in and of themselves may cause ataxia, likely contribute to key disabilities such as gait instability and falls. Based on the evolving available literature and experience, we outline a clinical approach to the diagnosis of adult-onset ataxia where a combination of cerebellar and peripheral or cranial nerve pathology exists. Objective diagnostic modalities including electrophysiology, oculomotor, and vestibular function testing are invaluable in accurately defining an individual's phenotype. Advances in MRI techniques have led to an increased recognition of disease-specific patterns of cerebellar pathology, including those conditions where neuronopathies may be involved. Depending on availability, a stepwise approach to genetic testing is suggested. This is guided by factors such as pattern of inheritance and age at disease onset, and genetic testing may range from specific genetic panels through to whole-exome and whole-genome sequencing. Management is best performed with the involvement of a multidisciplinary team, aiming at minimization of complications such as falls and aspiration pneumonia and maximizing functional status.

Glossary

CA=
cerebellar ataxia;
CABV=
cerebellar ataxia with bilateral vestibulopathy;
CANVAS=
cerebellar ataxia, neuronopathy, vestibular areflexia syndrome;
CIDP=
chronic inflammatory demyelinating polyradiculoneuropathy;
CMT=
Charcot-Marie-Tooth;
FRDA=
Friedreich ataxia;
GBS=
Guillain-Barre Syndrome;
FXTAS=
fragile X tremor ataxia syndrome;
MSA=
multiple system atrophy;
NIBS=
noninvasive brain stimulation;
SCA=
spinocerebellar ataxia;
vHIT=
video head impulse test;
VOR=
vestibulo-ocular reflex

The clinical manifestations of cerebellar impairment focus on the central concept of ataxia, which is often summarized as incoordination.1 Increasingly, the far-reaching influence of the cerebellum has resulted in an expanding understanding of the range of clinical expressions of cerebellar disease, which may affect a variable number of domains including, but not limited to, oculomotor, speech, appendicular, gait, and cognition and affect.2 Many clinical features are less than specific for cerebellar disorders, particularly in isolation, and these may include reduced speech intelligibility, motion-induced or spontaneous oscillopsia, and decreased dexterity. Gait disturbance, imbalance, and falls are nonspecific and may be caused by pathology affecting other systems, such as vestibular or somatosensory deficits.3

The noncerebellar manifestations of cerebellar diseases are increasingly recognized and find value in both clinical diagnosis and research progress.3 Previous publications have covered issues such as the existence of peripheral neuropathy in cerebellar diseases, so in this work, we aimed to aid the clinician in approaching patients with cerebellar presentations, particularly regarding extracerebellar pathologies that target ganglia, peripheral, and cranial nerves. Vestibulopathy is an increasingly recognized extracerebellar feature of cerebellar diseases, including the most common sporadic and inherited diseases: idiopathic late-onset cerebellar ataxia (CA)/sporadic late-onset CA, idiopathic cerebellar ataxia with bilateral vestibulopathy (CABV) spinocerebellar ataxia (SCA) 3 and 6, Friedreich ataxia (FRDA), and cerebellar ataxia, neuronopathy, vestibular areflexia syndrome (CANVAS)/RFC1-related disease. Vestibulopathy is not uncommonly believed to be the result of a likely cranial neuropathy (but is generally of uncertain pathology, given the lack of published temporal bone pathology in CAs).

A broad-based unsteady gait may be common to cerebellar, sensory, and vestibular impairment, and therefore, more specific signs are sought to identify or differentiate between these. Oculomotor abnormalities are highly specific, with many reflecting pathology of the cerebellum (and its connections), for example, saccadic visual pursuit, direction-changing nystagmus, and saccadic dysmetria,4 and a lesser number indicating vestibular pathology,5 for example, corrective saccades on performing the head impulse test.6 In addition to oculomotor signs, other more specific localizing abnormalities on examination include cerebellar dysarthria and appendicular ataxia, both seen in cerebellar impairment.7

Cerebellar and vestibular diseases resulting in ataxia may be accompanied by a peripheral neuropathy or neuronopathy.8,9 In addition, peripheral neuropathy or neuronopathy may be associated with vestibular and/or auditory neuropathy.10,11 In individuals with ataxia, identification and characterization of a neuropathy or neuronopathy (cranial, e.g., vestibular or peripheral) is important in defining a person's phenotype as a necessary step in progressing diagnosis and management.

A literature search of PubMed without date of publication limitation was performed using the terms “ataxia” OR “cerebell*” OR “neuropathy” OR “neuronopathy” OR “ganglionopathy” OR “polyneuropathy” OR “vestibulopathy,” with the results manually curated for relevance. If appropriate, primary sources quoted in references were also retrieved and curated. In this study, we focused on the clinical diagnosis of adult-onset ataxia that presents with the combination of cerebellar and peripheral or cranial nerve pathology.

Objective Functional Cerebellar Assessment

Objective assessment of cerebellar function (as opposed to structure, i.e., that accomplished by MRI) in most domains is yet to become clinically available; formal testing of vestibular and somatosensory function is readily available and should form an integral part of the clinical assessment of any individual with evidence of CA. The exception to the lack of objective assessment of cerebellar function is oculomotor measurement, which can be performed with a range of widely available video-oculography systems.12 Oculomotor testing is aimed at the identification of commonly seen abnormalities such as saccadic (or broken-up) pursuit, saccadic vestibulo-ocular (VOR) suppression, gaze-evoked nystagmus, dysmetric, latent, or slow saccades to target, and saccadic intrusions.4

Formal Vestibular Function Testing

Diagnosis of a vestibular component aids both the diagnostic process by potentially reducing the number of differential diagnoses and management, for instance, the addition of vestibular rehabilitation to the standard-of-care neurologic rehabilitation.13 Assessment of vestibular function may be performed by a facility that offers formal testing, and the modalities that are available to assess semicircular canal function are the video head impulse test (vHIT), rotational chair, and bithermal caloric irrigation.14 The otolith organs (utricle and saccule) are generally assessed by vestibular-evoked myogenic potentials15 or the subjective visual vertical (or horizontal) test.16 Given the ease of use, brevity of testing, and affordability, many clinicians now have a vHIT unit in their office, and we find this to be a very satisfactory screening test of vestibular involvement in our individuals with CA. It should be noted that the vHIT17 offers several advantages over the clinical HIT (cHIT) including abrogation of false-negative results due to the so-called covert corrective saccades, which are imperceptible to the clinician during the cHIT but clearly recorded by the vHIT.17 In addition, the vHIT offers excellent sensitivity,18 and the system may also be used to objectively test “cerebellar” oculomotor abnormalities such as visual pursuit, VOR suppression, and saccades to target. In addition, these units can be used to identify saccadic (or abnormal) visually enhanced VOR, which confirms the presence of combined bilateral vestibular hypofunction and cerebellar oculomotor dysfunction.19

Vestibular involvement in cerebellar syndromes may be due to a cranial neuropathy/neuronopathy, but regardless of its origin, its assessment is particularly valuable in establishing a patient's phenotype as a means of narrowing the range of differential diagnoses. It is worthwhile noting that although vestibular involvement in CAs is significant, otopathology is available only for very few cerebellar conditions, so whether the etiology is a vestibular neuropathy, vestibular neuronopathy, or end-organ pathology for most CAs is unknown. In the context of cerebellar diseases, vestibular involvement generally manifests as a bilateral hypofunction, affecting the semicircular canals,20 but may also involve the otolith organs, for example, where the vestibular ganglia are involved.21-23 The range of symptoms that accompany bilateral vestibular dysfunction include imbalance and motion-induced oscillopsia. Unfortunately, these symptoms are also seen in cerebellar disease, so they would be compatible with either cerebellar and/or vestibular impairment and, in the case of imbalance, somatosensory impairment as well. Therefore, in addition to electrophysiology, we advise vestibular function testing in all individuals with ataxia.

Neuropathy

When somatosensory loss is present, phenotypic assessment and nerve conduction studies can usually characterize the neuropathy/neuronopathy as axonal or demyelinating, large and/or small fiber, length dependent or nonlength dependent, and symmetric or asymmetric and determine the degree of motor and sensory involvement (Table 1). Impaired vibration and proprioception suggest large-fiber involvement, whereas paraesthesia, neuropathic pain, and burning sensations suggest small-fiber involvement. Our standard nerve conduction study protocol includes at least unilateral median, ulnar, radial, sural, and superficial peroneal antidromic sensory studies along with median, ulnar, fibular, and tibial motor studies. In addition, we find blink reflexes and mechanically activated masseter reflex helpful in assessing neuropathy and neuronopathy because neuropathy affects both tests, but in neuronopathy, the masseter reflex may not be affected because the cell bodies are in the brainstem. Autonomic involvement is suggested by a history of orthostatic dizziness, temperature intolerance, and bladder, gastrointestinal tract, and erectile dysfunction. The presence of any of these symptoms should lead to a careful examination and investigations to determine whether peripheral nerve dysfunction is associated with the overall disorder or whether it may be an incidental disorder, as previously shown in SCA 6.24

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1

Electrophysiologic Findings in Neuropathies/Neuronopathies

Balance depends on the integration of responses to sensory inputs from the vestibular, somatosensory, and visual systems. The vestibular and somatosensory systems react rapidly to acceleration of the head and to postural change and motion especially in the lower limbs, respectively. The visual system reacts later to stabilize the reactions to the earlier vestibular and somatosensory inputs. Therefore, if ataxia or imbalance is present only when visual inputs are removed (such as with eye closure or darkness), then proprioceptive sensory loss and/or vestibular dysfunction are likely.

Although in somatosensory disorders, there has been limited investigation of vestibular function, evidence suggests that vestibular and/or auditory neuropathy or neuronopathy is common, but possibly the slow onset of the conditions might obscure the vestibular component.25 When ataxia or imbalance is out of proportion to the objective somatosensory findings, then vestibular involvement should be considered. An ataxic gait is common in individuals with diabetes mellitus and may be associated with vestibulopathies or caused by hyperglycemia and changing glucose levels. Autonomic neuropathy often also contributes. Other neuropathies including Guillain-Barre syndrome (GBS), less commonly chronic inflammatory demyelinating polyradiculoneuropathy (CIDP),26 and inherited neuropathies are associated with cerebellar pathology and vestibular neuropathy. The combination of sensorineural hearing loss (in the case of FRDA, also auditory neuropathy) and vestibular neuropathy is seen in other diseases, including FRDA,27-29 Charcot-Marie Tooth (CMT) disease,30 and Refsum disease.31,32

In demyelinating neuropathies, vestibular dysfunction seems common. Frohman et al.33 in 1996 reported the first case of fluctuating vestibular syndrome paralleling the course and treatment of CIDP. Since then, several authors have confirmed vestibular involvement in CIDP and its variants, as well as GBS.25,26 Therefore, if ataxia is present with somatosensory loss and retained visual function, there is likely to be significant somatosensory loss, with or without vestibular dysfunction, and the latter should be investigated.

Similarly, in CMT, it has been shown that vestibular impairment is common, and it has been suggested that cervical vestibular myogenic potentials might be a more sensitive test than vHIT.34 It is not clear whether the neuropathy in these cases were demyelinating or axonal.

In axonal neuropathies, it is also suggested that vestibular neuropathy may be as common as in demyelinating neuropathies,10 but differing methodologies make this difficult to assess.11 Sensory neuronopathies may be acquired, usually of subacute onset, and may be paraneoplastic, immune mediated, infectious, toxic, idiopathic, or may be inherited, such as CANVAS and FRDA. These are associated with ataxia. Many of these have not been well investigated to assess the mechanism of ataxia, although in the most common phenotype of RFC1-related disease,21,35 CANVAS, the ataxia is also related to the vestibular ganglionopathy and the cerebellar pathology.22,36,37

Somatosensory disorders are a common and integral part of several of the spinocerebellar ataxias (SCAs). Peripheral neuropathy/neuronopathy is frequent in SCA1, SCA2, and SCA3,38 and although there are conflicting reports, it is probably not present in SCA6.24 A length-dependent neuropathy is an integral part of autosomal recessive spastic ataxia of Charlevoix-Saguenay.20 For guidance on the laboratory investigation of peripheral neuropathies, we refer the reader to Lau.39

Magnetic Resonance Imaging

Clinical radiologic assessment using MRI is often used after ataxia symptom presentation, particularly in the absence of an established genetic etiology, to qualitatively identify and grade any atrophy or detect lesions in the posterior fossa.23 However, the value of quantitative assessments of cerebellar, brainstem, and spinal cord macrostructure (i.e., atrophy), microstructure (i.e., diffusion), and even neurochemistry (i.e., spectroscopy) in differential diagnosis and disease monitoring of degenerative ataxias is becoming increasingly clear.40 The need for translation of quantitative research practices to the clinic is particularly salient, given the evidence that the clinical onset of ataxia may often be a late manifestation of well-advanced neuropathology or masked by the peripheral findings in a multisystem disease process. As such, we argue that there should be a low threshold to obtain neuroimaging of the brain and spinal cord in a person presenting with ataxia to evaluate for cerebellar, pontine, and dorsal column or corticospinal tract involvement particularly.

Assessment of precise cerebral and cerebellar anatomical involvement in different disease processes can be obtained via in vivo brain morphometry using MRI combined with postimaging automated software analysis such as voxel-based morphometry41 or feature-based anatomical image parcellation.40 Analogous approaches are also available for diffusion-weighted MRI, including tract-based spatial statistics and probabilistic tractography methods, to identify abnormalities in the integrity of different white matter tracts. These approaches have applications in identifying pathology relative to healthy control participants, as well as differentiating between disease entities with cerebellar involvement.

Quantitative research undertaken to date has largely focused on the inherited ataxias. In the SCAs, for example, degeneration is preferential in cerebellar lobules VII-IX in SCA2, additionally involves lobule VI and the medial anterior lobe in SCA3, while affecting lobules IX-X in SCA7. The disproportionate involvement of motor pathways in SCA3 correlates with the more severe motor phenotype. In FRDA, atrophy is preferentially localized to the cerebellar anterior lobe and superior cerebellar peduncle, although with increasing corticospinal and cerebral involvement with disease progression.42

In idiopathic progressive ataxias, research has principally focused on multiple system atrophy (MSA). Gray and white matter abnormalities in the posterior fossa appear to be restricted to the cerebellar variant of MSA (relative to the parkinsonian variant). Faber et al. also demonstrated that cerebellar degeneration occurs in individuals with both MSA–cerebellar subtype and sporadic late-onset CA, but that the brainstem and corticospinal tracts are affected only in those with MSA–cerebellar subtype.43 In individuals with CANVAS, case series have identified prominent involvement of cerebellar atrophy involving anterior and dorsal vermis, as well as crus I3. A recent quantitative analysis of a cohort of individuals with the RFC1 gene expansion also reported cerebellar degeneration largely weighted to the vermis, anterior lobe (lobules I–IV), and superior aspects of the posterior lobe (lobules V, VI and crus I). Subcortical structures were also strongly implicated, alongside a relevant sparing of the cerebral cortex.44

Neurodegenerative disorders causing chronic ataxia require different MRI acquisition protocols than those used in the diagnosis of other common neurologic disorders, such as stroke and epilepsy, although typically are broadly similar or equivalent to those used for other neurodegenerative and movement disorders. A major distinction for ataxias, however, is the additional value of spinal cord measures. Qualitative grading and quantitative measurements of cerebellar atrophy are also aided by higher-resolution images acquired at high field strengths (3T). Objective automated imaging analysis and MRI will continue to play an important role in the clinical evaluation of individuals with ataxia.

Genetic Testing

The first step in genetic analysis of ataxia is to draw a 3-generation pedigree. This will allow analysis of pattern of inheritance including autosomal dominant, autosomal recessive, X-linked, and mitochondrial. If the pedigree is consistent with autosomal-dominant, adult-onset ataxia, then testing for the common SCAs is the first genetic test. This will often include testing for the trinucleotide repeat expansions that underlie SCA 1, 2, 3, 6, and 7. This currently requires a stand-alone test because such expansions cannot be identified by genomic sequencing in most diagnostic laboratories. If no cause is found, then genomic sequencing should be considered to identify missense and nonsense pathogenic variants, as well as insertions, small deletions, and duplications as the cause. This can be whole-genome sequencing, whole-exome sequencing, or panel testing.

Ataxia in a young person should prompt testing for FRDA and ataxia telangiectasia (alpha fetoprotein is almost always elevated in the latter). Again, if no cause is found, then genomic testing should be considered. In an individual who has an onset of ataxia in adulthood where the family history is consistent with recessive inheritance or the individual is the only one in the family with the condition, in addition to testing for FRDA, testing for the biallelic pentanucleotide repeat expansion in RFC1 should take place. Testing by chromosomal microarray for copy number variants will occasionally diagnose the cause for ataxia such as SCA15, which is often due to a deletion of ITPR1. Testing for the CGG repeat expansion in FMR1 will enable the diagnosis of fragile X tremor ataxia syndrome (FXTAS).

Whole-genome sequencing can identify most genetic causes of ataxia including repeat expansions, point mutations, and copy number variants.45 The mitochondrial genome can be interrogated at the same time as the nuclear genome. Mitochondrial genome sequencing can identify several causes of ataxia with neuropathy such as neuropathy, ataxia, and retinitis pigmentosa, most commonly due to heteroplasmic point mutations in MT-ATP6. While whole-genome sequencing is currently relatively expensive, in the future, it is likely that this will be the first step in the genetic investigation of ataxia, removing the need for multiple individual tests.

For more detailed information on the genetic testing approach to ataxia, the reader is directed to Witek et al.46 For the general investigation of the etiology of CA, we refer the reader to previously published work.47 In the context of CA with a neuropathy or neuronopathy, after an objective investigation with electrophysiology and oculomotor and vestibular function testing, establishment of the individual's phenotype will guide genetic testing.

Multidisciplinary Management of Ataxia

Pharmaceutical intervention for the ataxias is constantly evolving and will not be a subject of this section. The foundation of successful management of ataxia lies with the multidisciplinary team, focused on management of the motor and nonmotor aspects of CA. Moreover, being familiar with clinical management guidelines is an essential component of evidence-based management of individuals with CA.48

We include the following in our routine management of individuals with the spectrum of diseases covered by this article in an effort to mitigate complications and aid the maintenance of functional status. In the first instance, it is crucial individuals with ataxia have access to multidisciplinary care including neurology, physiotherapy, occupational therapy, speech pathology, social work, audiology, and psychology (Table 2). In the context of there often being no “cure” for these conditions, regular review, instigation, and maintenance of appropriate medical and allied health management are the single most important interventions available to ensure a person with CA can maintain health and well-being for as long as possible. Without such intervention, the rate of progression and associated dependence and debility (including associated care costs) is significantly greater.49

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2

The Role of Members of a Multidisciplinary Team in Nonmotor and Motor Issues Related to Cerebellar Ataxia

Intensive neurorehabilitation has demonstrated efficacy in improving gait, coordination, functional status, health, and well-being in individuals with CA. In particular, regular access to periods of intensive neurorehabilitation supplemented by a targeted home-based activity program is important in maintaining function.50

Speech therapy aims to optimize verbal communication where cerebellar dysarthria is present,51 and given the risk of aspiration pneumonia, management of dysphagia is a management priority.52 The role of occupational therapy differs depending on the individual's circumstances, however, should comprise at a minimum an assessment of function in daily activities including participation in personal care, domestic, school, vocational, and community-based activities.53 The occupational therapist is crucial to identify the effect of changes in cognition and fatigue on functional performance. If necessary, prescription of assistive devices and/or advice regarding accessibility and safety in the home and community should be provided. Physiotherapy finds multiple applications including functional mobility and fall prevention.54 Spasticity, pain, and spasms are best managed by a multidisciplinary team that can offer physical therapy, focal and/or systemic medications, and application of orthoses.

More recently, noninvasive brain stimulation (NIBS) techniques have been the focus of multiple studies exploring the benefit of NIBS as a stand-alone and/or adjunct to traditional intervention for ataxia such as physiotherapy.55 In addition, a person with ataxia should undergo dual energy X-ray absoptiometry bone densitometry and bone health treatment as required in an effort to mitigate the potentially serious sequelae of falls.56 Finally, individuals with ataxia may have an increased risk of sleep disordered breathing that may necessitate regular surveillance and intervention as indicated.57,58

It seems likely that the expanding diversity in phenotypes of known CAs will continue. Similarly, new cerebellar diseases and genes will be discovered. These factors place an ever-increasing demand on detailed, objective assessment and characterization of our patients as a necessary step toward greater diagnostic acuity and, in a wider context, disease and treatment discovery.

Study Funding

No targeted funding reported.

Disclosure

The authors report no relevant disclosures. Go to Neurology.org/NG for full disclosures.

Footnotes

  • Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.

  • Submitted and externally peer reviewed. The handling editor was Massimo Pandolfo, MD, FAAN.

  • Received March 11, 2022.
  • Accepted in final form July 6, 2022.
  • Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Ashizawa T,
    2. Xia G
    . Ataxia. Continuum. 2016;22(4 Movement Disorders):1208–1226.
    OpenUrlPubMed
  2. 2.↵
    1. Koziol LF,
    2. Budding D,
    3. Andreasen N, et al.
    Consensus paper: the cerebellum's role in movement and cognition. Cerebellum. 2014;13(1):151-177.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Schniepp R,
    2. Möhwald K,
    3. Wuehr M
    . Gait ataxia in humans: vestibular and cerebellar control of dynamic stability. J Neurol. 2017;264(suppl 1):87-92.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kheradmand A,
    2. Zee DS
    . Cerebellum and ocular motor control. Front Neurol. 2011;2:53.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Schubert MC,
    2. Minor LB
    . Vestibulo-ocular physiology underlying vestibular hypofunction, Phys Ther. 2004;84(4):373-385.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Halmagyi GM,
    2. Curthoys IS
    . A clinical sign of canal paresis. Arch Neurol. 1988;45(7):737-739.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Bodranghien F,
    2. Bastian A,
    3. Casali C, et al.
    Consensus paper: revisiting the symptoms and signs of cerebellar syndrome. Cerebellum. 2016;15(3):369-391.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Liang L,
    2. Chen T,
    3. Wu Y
    . The electrophysiology of spinocerebellar ataxias. Neurophysiol Clin. 2016;46(1):27-34.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Szmulewicz DJ,
    2. McLean CA,
    3. Rodriguez ML, et al
    . Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS. Neurology. 2014;82(16):1410-1415.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Palla A,
    2. Schmid-Priscoveanu A,
    3. Studer A,
    4. Hess K,
    5. Straumann D
    . Deficient high-acceleration vestibular function in patients with polyneuropathy. Neurology. 2009;72(23):2009-2013.
    OpenUrlCrossRef
  11. 11.↵
    1. Buetti B,
    2. Luxon LM
    . Vestibular involvement in peripheral neuropathy: a review. Int J Audiol. 2014;53(6):353-359.
    OpenUrl
  12. 12.↵
    1. Edders SD,
    2. Zee DS
    1. Haslwanter T,
    2. Clarke AH
    . Eye movement measurement: electro-oculography and video-oculography. In: Edders SD, Zee DS editors. Handbook of Clinical Neurophysiology: Elsevier; 2010:61-79.
  13. 13.↵
    1. Hassannia F,
    2. Misale P,
    3. Sulway S, et al.
    Effectiveness of vestibular rehabilitation therapy in patients with idiopathic cerebellar ataxia with bilateral vestibulopathy (iCABV). J Vestib Res. Epub 2022 May 6.
  14. 14.↵
    1. Curthoys IS
    . The interpretation of clinical tests of peripheral vestibular function. Laryngoscope. 2012;122(6):1342-1352.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Colebatch JG,
    2. Halmagyi GM
    . Vestibular evoked potentials in human neck muscles before and after unilateral vestibular deafferentation. Neurology. 1992;(8): 1635-1635.
  16. 16.↵
    1. Friedmann G
    . The judgement of the visual vertical and horizontal with peripheral and central vestibular lesions. Brain. 1970;93(2):313-328.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. MacDougall HG,
    2. Weber KP,
    3. McGarvie LA,
    4. Halmagyi GM,
    5. Curthoys IS
    . The video head impulse test: diagnostic accuracy in peripheral vestibulopathy. Neurology. 2009;73(14):1134-1141.
    OpenUrlCrossRef
  18. 18.↵
    1. Halmagyi GM,
    2. Chen L,
    3. MacDougall HG,
    4. Weber KP,
    5. McGarvie LA and
    6. Curthoys IS
    . The video head impulse test. Front Neurol. 2017;8:258.
    OpenUrlCrossRef
  19. 19.↵
    1. Szmulewicz DJ
    . Combined central and peripheral degenerative vestibular disorders: CANVAS, idiopathic cerebellar ataxia with bilateral vestibulopathy (CABV) and other differential diagnoses of the CABV phenotype. Curr Otorhinolaryngol Rep. 2017;5:167-174.
    OpenUrl
  20. 20.↵
    1. Bouchard JP,
    2. Barbeau A,
    3. Bouchard R,
    4. Bouchard RW
    . Electromyography and nerve conduction studies in Friedreich's ataxia and autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Can J Neurol Sci. 1979;6(2):185-189.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Rafehi H,
    2. Szmulewicz DJ,
    3. Bennett MF, et al.
    Bioinformatics-based identification of expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS. Am J Hum Genet. 2019;105(1):151-165.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Szmulewicz DJ,
    2. Merchant SN,
    3. Halmagyi GM
    . Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome: a histopathologic case report. Otol Neurotol. 2011;32(8):e63-e65.
    OpenUrlPubMed
  23. 23.↵
    1. Deistung A,
    2. Stefanescu MR,
    3. Ernst TM, et al
    . Structural and functional magnetic resonance imaging of the cerebellum: considerations for assessing cerebellar ataxias. Cerebellum. 2016;15(1):21-25.
    OpenUrl
  24. 24.↵
    1. Zhang W,
    2. Jasinarachchi M,
    3. Seiderer L,
    4. Szmulewicz DJ,
    5. Roberts LJ
    . The electrophysiological findings in spinocerebellar ataxia type 6: evidence from 24 patients. J Clin Neurophysiol. Epub 2021 Apr 30.
  25. 25.↵
    1. Blanquet M,
    2. Petersen JA,
    3. Palla A, et al
    . Vestibulo-cochlear function in inflammatory neuropathies. Clin Neurophysiol. 2018;129(4):863-873.
    OpenUrl
  26. 26.↵
    1. Akdal G,
    2. Tanrıverdizade T,
    3. Şengün İ, et al.
    Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. J Neurol. 2018;265(2):381-387.
    OpenUrl
  27. 27.↵
    1. Rance R,
    2. Fava R,
    3. Baldock H, et al.
    Speech perception ability in individuals with Friedreich ataxia, Brain, 2008;131(8):2002-2012.
    OpenUrlCrossRefPubMed
  28. 28.
    1. Ell J,
    2. Prasher D,
    3. Rudge P
    . Neuro-otological abnormalities in Friedreich's ataxia. J Neurol Neurosurg Psychiatry. 1984;47(1):26-32.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Fahey MC,
    2. Cremer PD,
    3. Aw ST, et al.
    Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia. Brain. 2008;131(Pt 4):1035-1045.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Nadol JB Jr.,
    2. Hedley-Whyte ET,
    3. Amr SS,
    4. O Apos Malley JT,
    5. Kamakura T
    . Histopathology of the inner ear in charcot-marie-tooth syndrome caused by a missense variant (p.Thr65AL) in the MPZ gene. Audiol Neurootol. 2018;23(6):326.
    OpenUrl
  31. 31.↵
    1. Oysu C,
    2. Aslan I,
    3. Basaran B,
    4. Baserer N
    , The site of the hearing loss in Refsum's disease. Int J Pediatr Otorhinolaryngol 2001;61(2):129-134.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Taylor RL,
    2. Jankelowitz SK,
    3. Young AS,
    4. Sullivan D,
    5. Halmagyi GM,
    6. Welgampola MS
    . Reversible vestibular neuropathy in adult Refsum disease. Neurology. 2018;8;90(19):890-892.
    OpenUrl
  33. 33.↵
    1. Frohman EM,
    2. Tusa R,
    3. Mark AS,
    4. Cornblath DR
    . Vestibular dysfunction in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39(4):529-535.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Poretti A,
    2. Palla A,
    3. Tarnutzer AA, et al
    . Vestibular impairment in patients with Charcot-Marie-tooth disease. Neurology. 2013;80(23):2099-2105.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Cortese A,
    2. Simone R,
    3. Sullivan R, et al
    . Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. Nat Genet. 2019;51(4):649-658.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Ishai R,
    2. Seyyedi M,
    3. Chancellor AM, et al.
    The pathology of the vestibular system in CANVAS. Otol Neurotol. 2021;42(3):e332-e340.
    OpenUrl
  37. 37.↵
    1. Szmulewicz DJ,
    2. Roberts L,
    3. McLean CA,
    4. MacDougall HG,
    5. Halmagyi GM,
    6. Storey E
    . Proposed diagnostic criteria for cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS). Neurol Clin Pract. 2016;6(1):61-68.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Yadav R,
    2. Pal PK,
    3. Krishna N,
    4. Amar BR,
    5. Jain S,
    6. Purushottam M
    . Electrophysiological evaluation of spinocerebellar ataxias 1, 2 and 3. J Neurol Sci. 2012;15;(1-2):142-145.
    OpenUrl
  39. 39.↵
    1. Lau KHV
    . Laboratory evaluation of peripheral neuropathy. Semin Neuroll. 2019;39:531-541.
    OpenUrl
  40. 40.↵
    1. Öz G,
    2. Harding IH,
    3. Krahe J.
    4. Reetz K
    . MR imaging and spectroscopy in degenerative ataxias: towards multi-modal, multi-site, multi-stage monitoring of neurodegeneration. Curr Opin Neurol. 2020;33(4):451.
    OpenUrl
  41. 41.↵
    1. Kerestes R,
    2. Han S,
    3. Balachander S, et al
    . A standardized pipeline for examining human cerebellar grey matter morphometry using structural magnetic resonance imaging. J Vis Exp. 2022;4(180).
  42. 42.↵
    1. Harding IH,
    2. Chopra S,
    3. Arrigoni F, et al.
    Brain structure and degeneration staging in Friedreich ataxia: magnetic resonance imaging volumetrics from the ENIGMA‐ataxia working group. Ann Neurol. 2021;90(4):570-583.
    OpenUrl
  43. 43.↵
    1. Faber J,
    2. Giordano I,
    3. Jiang X, et al.
    Prominent white matter involvement in multiple system Atrophy of cerebellar type. Mov Disord. 2020;35(5):816–824.
    OpenUrl
  44. 44.↵
    1. Matos PCA,
    2. Rezende TJ,
    3. Schmitt GS, et al.
    Brain Structural signature of RFC1–related disorder. Mov Disord. 2021;36(11):2634-2641.
    OpenUrl
  45. 45.↵
    1. Tankard RM,
    2. Bennett MF,
    3. Degorski P,
    4. Delatycki MB,
    5. Lockhart PJ,
    6. Bahlo M
    . Detecting expansions of tandem repeats in cohorts sequenced with short-read sequencing data. Am J Hum Genet. 2018;103(6):858-873.
    OpenUrlCrossRef
  46. 46.↵
    1. Witek N,
    2. Hawkins J,
    3. Hall D
    . Genetic ataxias: update on classification and diagnostic approaches. Curr Neurol Neurosci Rep. 2021;21:13.
    OpenUrl
  47. 47.↵
    1. de Silva RN,
    2. Vallortigara J,
    3. Greenfield J,
    4. Hunt B,
    5. Giunti P,
    6. Hadjivassiliou M
    . Diagnosis and management of progressive ataxia in adults. Pract Neurol. 2019;19(3):196-207.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. de Silva R,
    2. Greenfield J,
    3. Cook A, et al.
    Guidelines on the diagnosis and management of the progressive ataxias. Orphanet J Rare Dis. 2019;14(1):51.
    OpenUrlPubMed
  49. 49.↵
    1. Fonteyn EM,
    2. Keus SH,
    3. Verstappen CC,
    4. Schöls L,
    5. de Groot IJ,
    6. van de Warrenburg BP
    . The effectiveness of allied health care in patients with ataxia: a systematic review. J Neurol. 2014;261:251-258.
    OpenUrlPubMed
  50. 50.↵
    1. Ilg W,
    2. Brötz D,
    3. Burkard S, et al.
    Long-term effects of coordinative training in degenerative cerebellar disease. Mov Disord. 2010;25:2239-2246.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Vogel AP,
    2. Stoll LH,
    3. Oettinger A et al.
    Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS. J Neurol. 2019;266;260-1266.
    OpenUrl
  52. 52.↵
    1. Ilg W,
    2. Branscheidt M,
    3. Butala A, et al
    . Consensus paper: neurophysiological assessments of ataxias in daily practice. Cerebellum. 2018;17(5):628-653.
    OpenUrl
  53. 53.↵
    1. Silva RC,
    2. Saute JA,
    3. Silva AC,
    4. Coutinho AC,
    5. Saraiva-Pereira ML,
    6. Jardim LB
    . Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz J Med Biol Res. 2010;43(6):537–542.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Ilg W,
    2. Bastian AJ,
    3. Boesch S, et al.
    Consensus paper: management of degenerative cerebellar disorders. Cerebellum 2014;13:248-268.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Manto M,
    2. Argyropoulos GPD,
    3. Bocci T, et al.
    Consensus paper: novel directions and next steps of non-invasive brain stimulation of the cerebellum in health and disease. 2021.
  56. 56.↵
    1. Farias AM,
    2. Appenzeller S,
    3. França MC, et al
    . Assessment of bone mineral density of patients with spinocerebellar ataxia type 3. J Mov Disord. 2019;12(1):43-46.
    OpenUrl
  57. 57.↵
    1. LaGrappe D,
    2. Massey L,
    3. Kruavit A
    . Sleep disorders among aboriginal Australians with machado-joseph disease: quantitative results from a multiple methods study to assess the experience of people living with the disease and their caregivers. Neurobiol Sleep Circadian Rhythms. 2022;12:100075.
    OpenUrlPubMed
  58. 58.↵
    1. Corben LA,
    2. Ho M,
    3. Copland J,
    4. Tai G,
    5. Delatycki MB
    . Increased prevalence of sleep disordered breathing in Friedreich ataxia. Neurology. 2013;81(1):40-45.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Study Funding
    • Disclosure
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Neurotology
  • EMG
  • MRI
  • Gait disorders/ataxia
  • Cerebellum

Alert Me

  • Alert me when eletters are published
Neurology Genetics: 9 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise